Regeneron - Eylea’s Growth Potential and Pipeline is Lucrative Enough!
Regeneron’s (REGN) growth trajectory will be sustained by the sales and upcoming label expansion of Eylea (aflibercept, VEGF-Trap Eye, L, wet-AMD, Central Retinal Vein Occlusion – CRVO, partnered with Bayer for ex-US) in Diabetic Macular Edema (DME) and myopic choroidal neovascularization (mCNV) and promise of the late-stage pipeline esp. anti-PCSK9 mAb, Alirocumab (REGN727, PhIII, Hypercholesterolemia, partnered with Sanofi). Not undermining the future potential of ... For more detail, please read our report released on Oct. 9, 2013 on REGN, titled, "Eylea’s Growth Potential and Pipeline is Lucrative Enough!"
More Publications
VERTEX , Positive Investment Alert - HCV/HIV Co-Infection – An Untapped Opportunity!
US$ 90.00
October 2011
4 pages
GILEAD SCIENCES - New HIV + HCV Products to Sustain the Growth Trajectory
US$ 140.00
January 2013
8 pages
Vertex - Near Term Positive Long Term Neutral
US$ 140.00
September 2011
5 pages
Meeting Expectations with Steady Growth- Trend to Continue
US$ 90.00
October 2011
5 pages
PHARMACYCLICS - Ibrutinib - Promising to Deliver More
US$ 140.00
January 2013
14 pages
